

## Technology Appraisal Committee A Interests Register

**Topic: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]**

**Publication Date: 07 May 2026**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Becky Pennington	TAC Committee Member	Direct - Financial Interests	<p>Becky has an ongoing methods research project with Pfizer on carers' HRQoL, paid to her employer UoS.</p> <p>She also hhas undertaken private consultancy work for Pierre Fabre in non-small cell lung cancer (ended July 2025)</p> <p>Becky has undertaken private consultancy work for Pierre Fabre, for different drugs (not vinorelbine) in a different indication (not breast cancer).</p>	<p>12/02/2026</p> <p>09/09/2025</p>	It was agreed that Becky Pennington's declaration would not prevent her from participating in discussions on this appraisal
Hugo Pedder	TAC Committee Member	Indirect Financial Interests	<p>Hugos' employer, ConnectHEOR has been awarded a contract to work with Daiichi Sankyo</p> <p>It's for breast cancer, but for a different line of therapy, and I have</p>	<p>09/03/2026</p> <p>12/02/2026</p> <p>07/10/2025</p>	It was agreed that Hugo Pedder's declaration would not prevent him from participating in discussions on this appraisal

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>no involvement in any way on that work.</p> <p>So it'd definitely be an indirect financial conflict of interest (I've already submitted one for this appraisal for Roche), related to the technology. I'm not 100% sure whether it counts as being related to the indication or not if it is for a different line of therapy.</p> <p>Hugo has performed work for Roche in the last 12 months on behalf of his employer, ConnectHEOR, on an unrelated technology and indication.</p> <p>Hugo is employed by ConnectHEOR to do work for Roche on a technology and indication unrelated to the current appraisal, which will start later this week (post 07/10/2025)</p>		
Zoe Philips	TAC Committee Member	Financial Interests	Zoe has provided consultancy to the company for this product in this indication	16/02/2026 11/09/2025	It was agreed that Zoe Philips' declaration would prevent her from

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
					participating in discussions on this appraisal
Min Ven Teo	TAC Committee Member	Financial Interests	Employer receives grant from Daichii Sankyo for AF case finding work	15/09/2025	It was agreed that Min Ven Teo's declaration would not prevent him from participating in discussions on this appraisal
Nicole Droste	Patient Expert	Non-Financial	Volunteer for patient advocacy charity Metupuk	09/02/2026 07/10/2025	It was agreed that Nicole Droste's declaration would not prevent her from providing expert advice to the committee.